US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017
Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.
Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.